“China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” commented Scott Houlton, President of Development and Clinical Services at Catalent.
Somerset, NJ (PRWEB) November 13, 2013
Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, today announced that construction and validation of its Clinical Supply facility in Shanghai, China has been completed. Catalent business leaders, local employees, customers and partners celebrated at a site opening ceremony on November 8th, 2013, less than 9 months after construction began on the site.
It is the first clinical supply facility in China to provide end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution. The facility is also validated to support biologics requiring refrigerated and frozen supply chain management. Catalent has already secured customer projects for the site, which is now undergoing customer validation for the supply of clinical trial materials.
Catalent currently supports the clinical trial supply needs of the top 25 pharmaceutical companies and more than 300 small innovators from all over the world. The new, state-of-the-art, 31,000 square foot facility has been constructed to the company’s proven ‘center of excellence’ guidelines and will operate to Catalent’s global Quality Management System. The Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. facility is the eighth in Catalent’s global clinical supply network and is located in Shanghai’s Waigaoqiao Free Trade Zone.
“China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” commented Scott Houlton, President of Development and Clinical Services at Catalent. “Having started work on our China clinical supply strategy two years ago, I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”
Dr. Weiyan “Jackson” Zhu, Catalent's Country General Manager for China added, “The recently appointed local management team brings a huge combined prior experience of clinical trials management, pharmaceuticals and healthcare. Together with Catalent’s GMP facility in Singapore, the company is well positioned to serve the clinical trials needs of our regional and global customers.”
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com.
More products. Better treatments. Reliably supplied.™
June 20, 2013: “Catalent Officially Launches New Capabilities at CPhI China”
April 16, 2013: “Catalent Announces Two Senior Appointments to Drive Growth in China”
March 11, 2013: ”Catalent Announces Major China Expansion with Two New Facilities for Softgel Technologies and Clinical Supply Solutions Businesses”
Catalent’s location in Shanghai and capabilities.